Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14

Executive Summary

• Hemostemix announced its participation in the Innovations in Wound Healing 2025 conference in Key West, Florida.
• The company highlighted multiple peer‑reviewed clinical studies demonstrating significant efficacy of its ACP‑01 (VesCell™) therapy for chronic limb‑threatening ischemia (CLTI), including high limb‑salvage rates and reduced mortality.
• ACP‑01 is now legally available in Florida under SB 1768, allowing immediate patient access through compliant medical practices.

Key Details

• Conference Attendance: Innovations in Wound Healing 2025, Key West, FL (Dec 11‑14, 2025). Hemostemix will present its regenerative medicine platform and clinical data.
• Clinical Evidence Cited:
• Henderson et al., J Biomed Res Environ Sci. 2024 – restored perfusion & wound healing in no‑option CLTI patients.
• Mutirangura et al., Journal of the Medical Association of Thailand, 2009 – 83 % limb salvage.
• UBC & University of Toronto poster, 2023 – 0 % mortality, improved perfusion, 83 % functional outcome improvement.
• Szabo et al., Cytotherapy 2013 – 0 % mortality, 70 % limb salvage vs. 20 % limb loss in standard care.
• Phase II Trial Results (CLTI):
• 12 patients treated; 11 (83 %) received VesCell™.
• Ulcer size reduced from mean 146 mm² to 0.48 mm² by 3 months (p = 0.01).
• One amputation (4.8 %) and one death (4.8 %) in treatment arm vs. higher rates in placebo.
• Regulatory Availability: Florida SB 1768 permits ACP‑01 to be administered today to patients with PAD, CLTI, and other ischemic vascular diseases.
• Therapeutic Benefits Claimed: Increased perfusion, improved exercise capacity, reduced ischemic pain, accelerated wound healing, restored mobility, enhanced quality of life.
• CEO Statement: Thomas Smeenk emphasized early treatment to avoid irreversible damage and highlighted the need for a shift in standard care.

Notable Quotes

“There is no logical or medical justification for waiting until PAD causes irreversible ischemic damage. Early restoration of circulation is the rational, humane, and evidence‑based approach.” – Thomas Smeenk, CEO

Materiality Assessment: Material – Positive (the release provides substantive clinical efficacy data and announces immediate market availability in Florida, which could materially affect the company’s commercial outlook).